



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**Date Submitted: December 28, 2010

(use as many sheets as necessary)

Sheet 1 of 13**Complete if Known**

Application Number	10/525,913
Filing Date	09/08/2005
First Named Inventor	HOLTUS
Art Unit	1781
Examiner Name	Kelly Jo Bekker
Attorney Docket Number	069818-1250

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	B1	3,956,228	05/11/1976	NOGAMI	
	B2	4,237,118 A1	12/02/1980	HOWARD	
	B3	4,412,946	11/01/1983	ZALISZ et al	
	B4	5,292,723	03/08/1994	AUDRY et al	
	B5	5,374,657	12/20/1994	KYLE	
	B6	5,444,054	08/22/1995	GARLEB et al	
	B7	5,472,952	12/05/1995	SMIDT et al	
	B8	5,502,041 A1	03/26/1996	MOEN et al	
	B9	5,531,988 A	07/02/1996	PAUL	
	B10	5,629,023 A1	05/13/1997	BLAND	
	B11	5,629,040 A	05/13/1997	TAKEMORI et al	
	B12	5,733,579 A	03/31/1998	WOLF et al	
	B13	5,744,134 A	04/28/1998	PAUL	
	B14	5,773,094	06/30/1998	KRUCKEL	
	B15	5,776,887 A	07/07/1998	WIBERT et al	
	B16	5,792,754 A	08/11/1998	GREEN et al	
	B17	5,840,361 A	11/24/1998	THEUER et al	
	B18	5,846,569	12/08/1998	ANDERSON et al.	
	B19	5,882,648 A1	03/16/1999	YORHIHARA et al	
	B20	6,051,260 A1	04/18/2000	LISKA et al	
	B21	6,197,758 B1	03/06/2001	OHTSUKI et al	
	B22	6,231,889 B1	05/15/2001	RICHARDSON et al	
	B23	6,337,137 B1	01/08/2002	KOLDIJK et al	
	B24	6,451,584 B2	09/17/2002	TOMITA et al.	
	B25	6,468,987 B1	10/22/2002	DEMICHELE et al	
	B26	6,576,251 B1	06/10/2003	STAHL et al	
	B27	6,632,445	10/14/2003	RICHARDSON et al	
	B28	6,737,089	05/18/2004	WADSWORTH et al	
	B29	6,794,495 B1	09/21/2004	Sorensen et al.	
	B30	6,846,501	01/25/2005	PROSISE et al	
	B31	6,974,841 B1	12/13/2005	RAPISARDA et al.	
	B32	7,351,715	04/01/2008	RICHARDSON et al	
	B33	7,576,070	08/18/2009	KUNZ et al	
	B34	7,601,364	10/13/2009	SWATZKI	
	B35	2002-0016289 A1	02/07/2002	CONNELLY et al.	
	B36	2002-0044988 A1	04/18/2002	FUCHS et al	
	B37	2003-0022863 A1	01/30/2003	STAHL et al	
	B38	2003-0165604	09/04/2003	TSUBAKI et al	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u>  (use as many sheets as necessary)				Application Number	10/525,913
				Filing Date	09/08/2005
				First Named Inventor	HOLTUS
				Art Unit	1781
				Examiner Name	Kelly Jo Bekker
Sheet	2	of	13	Attorney Docket Number	069818-1250

U.S. PATENT DOCUMENTS					
		Document Number			
	B39	2004-0122105 A1	06/24/2004	BETTLE et al.	
	B40	2004-0219188 A1	11/04/2004	COMER et al	
	B41	2007/0036839 A1	02/15/2007	Tuduri et al.	
	B42	2007-0166446 A1	07/19/2007	BOURSIER	
	B43	2008-0015166 A1	01/17/2008	VAN TOL	
	B44	2008-0138435 A1	06/12/2008	VAN DEN BERG	
	B45	2008-0171720 A1	07/17/2008	GARSSEN et al	
	B46	2008-0207559 A1	08/28/2008	SAWATZKI et al	
	B47	2009-0082249 A1	03/26/2009	GARSSEN et al	
	B48	2010-0016214 A1	01/21/2010	SAWATZKI et al	
	B49	2010-0069320 A1	03/18/2010	SPEELMANS et al	
	B50	2010-0167982 A1	07/01/2010	VAN TOL et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	B51	AU 1997/28718 B2	07/17/1997	Raffinerie Tirlemontoise		
	B52	DE 28 44 861 A1	04/30/1980	Pharma Hameln Kerstein Gmbh		
	B53	DE 37 34962 C1	01/05/1989	Luitpold Wrk Chem Pharm		
	B54	DE 199 40 011 A1	03/01/2001	Elorisan GmbH i.K.		
	B55	DE 100 27 050 A1	12/13/2001	Balan, Karim		
	B56	DE 101 36 260 A1	02/13/2003	Suedzucker AG		
	B57	EP 0 307 523 B1	03/24/1993	Kabushiki Kaisha Yakult Honsha		
	B58	EP 0 355 905 A1	02/28/1990	Akzo NV		
	B59	EP 0 378 824 B1	07/25/1990	Chimicasa GMBH		
	B60	EP 0 382 355 B1	08/16/1990	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo		
	B61	EP 0 504 055 A 1	09/16/1992	Roussel-Uclaf		
	B62	EP 0 511 761 A1	11/04/1992	Cerestar Holding BV		
	B63	EP 0 593 774 B1	04/27/1994	Otsuka Pharma Co Ltd		
	B64	EP 0 596 717 A1	05/11/1994	Chandra Consultants		
	B65	EP 0 615 752 A1	09/21/1994	Scotia Holdings PLC		
	B66	EP 0 641 562 A1	03/08/1995	Sandoz Nutrition LTD.		
	B67	EP 0 692 252 A1	01/17/1996	Raffinerie Tirlemontoise		
	B68	EP 0 705 539 A2	04/10/1996	Friesland Brands BV		
	B69	EP 0 711 503 A2	05/15/1996	Scotia Holdings PLC		
	B70	EP 0 745 001 B1	11/25/1998	KSK Industrielackierungen GmbH		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u>  <i>(use as many sheets as necessary)</i>				Application Number	10/525,913
				Filing Date	09/08/2005
				First Named Inventor	HOLTUS
				Art Unit	1781
				Examiner Name	Kelly Jo Bekker
Sheet	3	of	13	Attorney Docket Number	069818-1250

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B71	EP 0 756 828 B1	11/18/1998	N.V. Nutricia		
	B72	EP 0 941 088 B1	03/05/2003	Wisconsin Alumni Research Foundation		
	B73	EP 0 958 825 A1	11/24/1999	Henryk, et al		
	B74	EP 1 105 002 B1	07/17/2002	Nutricia NV		
	B75	EP 1 155 627 A1	11/21/2001	Belovo Eggs & Egg Products		
	B76	EP 1 321 527 A1	06/25/2003	Amano Enzyme Inc.		
	B77	EP 1 454 990 B1	02/22/2006	Suntory Limited		
	B78	EP 1 597 978 A1	11/23/2005	Nutricia N.V.		
	B79	EP 1 721 611 A1	11/15/2006	N.V. Nutricia		
	B80	EP 1 723 951 A1	11/22/2006	N.V. Nutricia		
	B81	FR 2 781 673 A1	02/04/2000	Universite de Picardie Jules Verne		
	B82	FR 2 866 203 A1	08/19/2005	Roquette Freres		
	B83	GB 1305071	01/31/1973	Deutsche Laevosan-Gellschaft, et al.		
	B84	JP 53-42340 A	11/10/1978	Asahi Chem. Ind. Co. Ltd.		
	B85	JP 2-286058 A	11/26/1990	Nippo Synthetic Chem Ind		
	B86	JP 08-151328 A	06/11/1996	Fuji Latex KK		
	B87	JP 9-065855 A	03/11/1997	Otsuka Shokuhin KK		
	B88	JP 10-175867 A	06/30/1998	Morinaga Milk Industry Col., Ltd., et al.		
	B89	JP 2003 146887 A	05/21/2003	Gotoo Corp. KK		
	B90	WO 92/22588 A1	12/23/1992	Italfarmaco SPA		
	B91	WO 95/26646 A1	10/12/1995	Abbot Laboratories		
	B92	WO 96/13271 A1	05/09/1996	Metagenics Inc.		
	B93	WO 97/02829 A2	01/30/1997	Abbot Laboratories		
	B94	WO 97/34615 A1	09/25/1997	Brown, et al		
	B95	WO 98/11910 A1	03/26/1998	Scient Hospital Supply Int Ltd		
	B96	WO 98/15196 A1	04/16/1998	Meiji Seika Kaisha, Ltd.		
	B97	WO 98/26787 A1	06/25/1998	Arnott s Biscuits, Ltd.		
	B98	WO 98/31241 A1	07/23/1998	N.V. Nutricia		
	B99	WO 99/53777 A1	10/28/1999	Novartis Nutrition AG		
	B100	WO 2000/08948 A2	02/24/2000	N.V. Nutricia		
	B101	WO 01/41581 A1	06/14/2001	N.V. Nutricia		
	B102	WO 01/60378 A2	08/23/2001	N.V. Nutricia		
	B103	WO 01/78530 A2	10/25/2001	Abbott Laboratories		
	B104	WO 02/42484 A2	05/30/2002	Sudzucker Aktiengesellschaft Mannheim/Ochsenfurt		
	B105	WO 02/047612 A2	06/20/2002	Mannatech Inc.		
	B106	WO 02/076471 A1	10/03/2002	Societe des Produits Nestle S.A.		
	B107	WO 03/093322 A2	11/13/2003	Population Council Inc.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u> <i>(use as many sheets as necessary)</i>				Application Number	10/525,913
				Filing Date	09/08/2005
				First Named Inventor	HOLTUS
				Art Unit	1781
				Examiner Name	Kelly Jo Bekker
Sheet	4	of	13	Attorney Docket Number	069818-1250

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B108	WO 2004/000042 A2	12/31/2003	N.V. Nutricia		
	B109	WO 2004/000340 A2	12/31/2003	N.V. Nutricia		
	B110	WO 2004/026294 A1	04/01/2004	Novartis Nutrition AG		
	B111	WO 2004/052121 A1	06/24/2004	Novartis Nutrition AG		
	B112	WO 2004/112508 A1	12/29/2004	Nestec S.A.		
	B113	WO 2004/112509 A2	12/29/2004	Nestec S.A.		
	B114	WO 2004/113415 A1	12/29/2004	DSM IP Assets B.V.		
	B115	WO 2005/039319 A2	05/06/2005	N.V. Nutricia		
	B116	WO 2005/039597 A2	05/06/2005	N.V. Nutricia		
	B117	WO 2005/067955 A1	07/28/2005	Stamets et al.		
	B118	WO 2005/110121 A1	11/24/2005	N.V. Nutricia		
	B119	WO 2005/122790 A1	12/29/2005	N.V. Nutricia		
	B120	WO 2006/007676 A1	01/26/2006	Amazonia Fitomedicamentos Ltda		
	B121	WO 2006/014519 A1	02-09-2006	Elmaleh, David		
	B122	WO 2006/112694 A2	10/26/2006	N.V. Nutricia		
	B123	WO 2006/112716 A2	10/26/2006	N.V. Nutricia		
	B124	WO 2006/112717 A2	10/26/2006	N.V. Nutricia		
	B125	WO 2007/016132 A2	02/08/2007	Alcon Refractivehorizons, Inc.		
	B126	WO 2007/115210 A2	10/11/2007	Nutracea Inc.		
	B127	WO 2009/096772 A1	08/06/2009	N.V. Nutricia		
	B128	WO 2009/096789 A1	08/06/2009	N.V. Nutricia		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	B129	AIDS Fact Sheet: T-cell tests; also available at <a href="http://web.archive.org/web/20040217112225/http://www.aids.org/factSheets/124-T-Cell-Tests.html">http://web.archive.org/web/20040217112225/http://www.aids.org/factSheets/124-T-Cell-Tests.html</a> , published 2004; last viewed Oct. 21, 2009	
	B130	ALTER et al., "Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection," <i>Blood</i> , vol. 106, no. 10, Nov. 15, 2005, pp 3366-3369	
	B131	Analysis of RAFTIMIX 10; RAFTIMIX® ST and RAFTILOSE® P95, (1995)	
	B132	Anonymous, "Larch Arabinogalactan," <i>Alternative Medicine Review</i> , vol. 5, no. 5, 2000, pp. 463-466	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u> <i>(use as many sheets as necessary)</i>				Application Number	10/525,913
				Filing Date	09/08/2005
				First Named Inventor	HOLTUS
				Art Unit	1781
				Examiner Name	Kelly Jo Bekker
Sheet	5	of	13	Attorney Docket Number	069818-1250

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	B133	BERNHART et al., "Lactulose in Modified Milk Products for Infant Nutrition," <u>J. Dairy Sci.</u> , 1956, pp. 399-400		
	B134	BOEHM et al., "Supplementation of a bovine milk formula with an oligosaccharide mixture increases counts of faecal bifidobacteria in preterm infants," <u>Fetal &amp; Neonatal</u> , vol. 86, no. 3, May 2002, pp. F178-F181		
	B135	BOEHM, "Prebiotic concept for infant nutrition," <u>Acta Paediatrica Suppl.</u> , vol. 441, 2003, pp. 64-67		
	B136	BOEHM et al., "Prebiotics and Immune Responses," <u>Journal of Pediatric Gastroenterology and Nutrition</u> , vol. 39, Jun. 2004, pp. S772-S773		
	B137	BOERSMA et al., "Vitamin E, lipid fractions, and fatty acid composition of colostrum, transitional milk, and mature milk: an international comparative study," <u>American Journal of Clinical Nutrition</u> , Dep. Of Obstetrics & Gynaecology, State Univ. Groningen, EZ Groningen 9713, Netherlands, vol. 3, no. 5, 1991, p. 1197-1204		
	B138	BOUHNIEK et al., "Administration of Transgalacto-Oligosaccharides Increases Fecal Bifidobacteria and Modifies Colonic Fermentation Metabolism in Healthy Humans," <u>American Society for Nutritional Sciences</u> , 1997 pp. 444-448		
	B139	BREITKREUTZ et al., "Improvement of immune functions in HIV infection by sulfur supplementation: Two randomized trials," <u>Journal of Molecular Medicine</u> (Berlin), vol. 78, no. 1, 2000, pp. 55-62		
	B140	BUCKLER, "Prebiotics in infant nutrition," Internet article online Jul. 8, 2001, pp. 1-5 (XP002292254), retrieved from the Internet: <u>URL:http://www.se-neonatal.es/se-neonatal/oviedo2001/prebiotics.pdf</u> on Aug. 11, 2004		
	B141	CHO et al., <u>Complex Carbohydrates in Foods</u> , Marcel Dekker Inc., NY, 1999, pp. 229-233, 246 (ISBN: 0-8247-0187-9)		
	B142	<u>CODEX STAN 72</u> , "Standard For Infant Formula And Formulas For Special Medical Purposes Intended For Infants," 1981, pp. 1-21		
	B143	CRAIG et al., "Polydextrose as Soluble Fiber: Physiological and Analytical Aspects," <u>American Assn of Cereal Chemists, Inc.</u> , vol. 43, no. 5, May 1998, pp. 370-376 (publication no. W-1998-0427-03F)		
	B144	CRITTENDEN et al., "Production, properties and applications of food-grade oligosaccharides," <u>Trends in Food Science &amp; Technologies</u> , vol. 7, Nov. 1996. pp. 353-361		
	B145	CUMMINGS, "Gastrointestinal Effects of Food Carbohydrate.supp.1-3," <u>Am J Clin Nutr</u> , Apr. 1995; Suppl. 4 61 (suppl): pp. 938S-945S		
	B146	Database CA 'Online! Chemical Abstracts Service, Columbus, Oh, NOGAMI, "Resin Compositions for low-temperature curable powder paints," retrieved from STN Database accession no. 87:137415 abstract & JP 53 042340 B, Nov. 10, 1978		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u> <i>(use as many sheets as necessary)</i>				Application Number	10/525,913
				Filing Date	09/08/2005
				First Named Inventor	HOLTUS
				Art Unit	1781
				Examiner Name	Kelly Jo Bekker
Sheet	6	of	13	Attorney Docket Number	069818-1250

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	B147	Database Medline [Online], US NLM, Dec. 1994, MALORNI et al.: "Thiol supplier N-acetylcysteine enhances conjugate formation between natural killer cells and K562 or U937 targets but increases the lytic function only against the latter," Database accession no. NLM7721335, & Immunology Letters, vol. 43, no. 3, Dec. 1994, 1 page [XP002474080]	
	B148	Database WPI, Section Ch. Week 198929, Derwent Publications Ltd., London, GB, Class B03, AN 1989-211474	
	B149	Database WPI, Section Ch. Week 199615, Derwent Publications Ltd., London, GB, Class B04, AN 1996-145913	
	B150	Database WPI Week 199633, Derwent Publications, Ltd., London, GB: AN 1996-329426 [XP-002426042]	
	B151	Database WPI, Section Ch, Week 200261, Derwent Publications Ltd., London, GB, Class A26, AN 2002-567199 & CN 1 343 727 A, Apr. 10, 2002 [XP-002344565]	
	B152	Database WPI, Week 200634, Derwent Publications Ltd., London, GB, AN 2006-323978 & JP 2006 115826 A, May 2006 [XP-002474081]	
	B153	DETRY, Dissertation, 1992, Institute Paul Lambin "Implications technologiques et nutritionnelles..."	
	B154	DOMBO et al., "Production Health Benefits and Applications of Galacto-oligosaccharides," Yalpani M. ed., New Technologies for Healthy Foods and Nutraceuticals, ATL Press, Shewsbury, MA, 1997, pp. 143-156	
	B155	DONGOWSKI et al., "The Degree of Methylation Influences the Degradation of Pectin in the Intestinal Tract of Rats In Vitro," <u>The Journal of Nutrition</u> , vol. 132, 2002, pp. 1935-44	
	B156	DROEGE, "Cysteine and glutathione deficiency in AIDS patients: A rationale for the treatment with N-Acetyl-Cysteine," <u>Pharmacology</u> (Basel), vol. 46, no. 2, 1993, pp. 61-65	
	B157	DROEGE et al, "Is AIDS the consequence of a virus-induced cysteine and glutathione deficiency? Chances and limitations of the treatment with N-acetyl-cysteine (NAC)," <u>AIDS Research and Human Retroviruses</u> , vol. 10, no. Suppl. 3, 1994, p. S65 (XP008052583)	
	B158	DROEGE et al., "Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction," <u>FASEB Journal</u> , vol. 11, no. 13, Nov. 1997, pp. 1077-1089	
	B159	DROEGE et al., "Glutathione and immune function," <u>Proceedings of the Nutrition Society</u> , vol. 59, no. 4, Nov. 2000, pp. 595-600	
	B160	ELFSTRAND et al., "Immunoglobulins, growth factors and growth hormone in bovine colostrum and the effects of processing," <u>International Dairy Journal</u> , vol. 12, 2002, pp. 879-887	
	B161	Elix'or® "Galacto-oligosaccharides for Innovative Foods," Borculo Whey Products product information material	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/525,913
		<b>Filing Date</b>	09/08/2005
Date Submitted: <u>December 28, 2010</u> (use as many sheets as necessary)		<b>First Named Inventor</b>	HOLTUS
		<b>Art Unit</b>	1781
Sheet <u>7</u> of <u>13</u>		<b>Examiner Name</b>	Kelly Jo Bekker
		<b>Attorney Docket Number</b>	069818-1250

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	B162	Elix'or® "Galacto-oligosaccharides: A natural ingredient for functional foods," <u>Borculo Whey Products product information brochure</u> , Jul. 1996	
	B163	FACCHINI et al., "Increased number of circulating Leu 11+ (CD 16) large granular lymphocytes and decreased NK activity during human ageing," <u>Clinical Experimental Immunology</u> , vol. 68, no. 2, 1987, pp. 340-347	
	B164	FANARO et al., "Galacto-oligosaccharides and long-chain fructo-oligosaccharides as prebiotics in infant formulas: A review," <u>Acta Paediatrica Suppl.</u> , vol. 94, sup. 449, 2005, pp. 22-26	
	B165	FERRANDEZ et al.: "Effects in vitro of several antioxidants on the natural killer function of aging mice - differing roles for IFN-gamma and IL-2," <u>Experimental Gerontology</u> , vol. 34, no. 5, Aug. 1999, pp. 675-685 [XP002474079]	
	B166	FIBRULINE® Instant, Certificate of Analysis, Cosucra B.V., Netherlands, Oct. 12, 1994, 1 page	
	B167	FIDLER et al., "Polyunsaturated fatty acid composition of human colostrum lipids in Slovenia: regional differences," <u>Food Technology and Biotechnology</u> , vol. 38, no. 2, 2000, pp. 149-153, Biotech. Fac., Inst. Of Nutr., Univ. of Ljubljana, SI-1230 Domzale, Slovenia	
	B168	FIDLER et al., "The fatty acid composition of human colostrum," <u>European Journal of Nutrition</u> , vol. 39, no. 1, Feb. 2000, pp. 31-37	
	B169	FRISOMUM, Analysis Chart and Brochure, 1998	
	B170	GHONEUM et al., "Production of Tumor Necrosis Factor-Alpha and Interferon-Y from Human Peripheral Blood Lymphocytes by MGN-3, a Modified Arabinoxylan from Rice Bran, and Its Synergy with Interleukin-2 In Vitro," <u>Cancer Detection and Prevention</u> , vol. 24, no. 4, 2000, pp. 314-324	
	B171	GHONEUM et al., "Enhancement of Natural Killer Cell Activity of Aged Mice by Modified Arabinoxylan Rice Bran (MGN-3/Biobran)," <u>J. Pharm. and Pharmacology</u> , vol. 56, no. 12, Dec. 2004, pp. 1581-1588	
	B172	GIBSON, "Bifidogenic properties of different types of fructo-oligosaccharides," <u>Food Microbiology</u> , vol. 11, 1994, pp. 491-498	
	B173	GIBSON et al., "Selective stimulation of bifidobacteria in the Human Colon by Oligofructose and Inulin," <u>Gastroenterology</u> , vol. 108, 1995, pp. 975-982	
	B174	GIBSON et al., "Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics," <u>Journal of Nutrition</u> , vol. 125, 1995, pp. 1401-1412	
	B175	GLADE, "Nutrition, Nutritional Pharmaceuticals," <u>Conference Summary: First Symposium of the International College of Advanced Longevity Medicine</u> , Reno, Nevada, October 11-13, 1998," vol. 16, issue 9, 2000, pp. 789-790	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u>  (use as many sheets as necessary)		Application Number	10/525,913
		Filing Date	09/08/2005
		First Named Inventor	HOLTUS
		Art Unit	1781
		Examiner Name	Kelly Jo Bekker
		Attorney Docket Number	069818-1250
Sheet	8	of	13

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	B176	GONZALEZ et al., "Polysaccharides as Antiviral Agents: Antiviral Activity of Carrageenan," <u>Antimicrobial Agents and Chemotherapy</u> , vol. 31, no. 9, Sep. 1987, pp. 1388-1393	
	B177	HAASTRECHT, "Oligosaccharides: Promising Performers in New Product Development," <u>IFI</u> , no. 1, 1995, pp. 23-27	
	B178	HARMSSEN et al., "Analysis of Intestinal Flora Development in Breast-Fed and Formula-Fed Infants by Using Molecular Identification and Detection Methods," <u>J. Pediatr. Gastroenterol. Nutr.</u> , vol. 30, 2000, pp. 61-67	
	B179	HARTEMINK "Non-digestible oligosaccharides: healthy food for the colon?," Proceedings of the International Symposium, <u>Wageningen Pers</u> , NL, Dec. 4-5, 1997, pp. 130-131 (ISBN 90-74134-52-1)	
	B180	HAUER et al., "Mechanism of Stimulation of Human Natural Killer Cytotoxicity by Arabinogalactan from <i>Larix Occidentalis</i> ," <u>Cancer Immuno. Immunotherapy</u> , vol. 36, no. 4, 1993, pp. 237-244	
	B181	HERTZLER et al., "Colonic Adaptation to Daily Lactose Feeding in Lactose-Maldigesters Reduces Lactose-Intolerance," <u>Am. J. Clin. Nutr.</u> , 1996, pp. 232-236	
	B182	HIRAYAMA, "Novel physiological functions of oligosaccharides," <u>Pure Appl. Chem.</u> , vol. 74, no. 7, 2002, pp. 1271-1279	
	B183	HOPKINS et al., "Nondigestible Oligosaccharides Enhance Bacterial Colonization Resistance against <i>Clostridium difficile</i> In Vitro," <u>Applied and Environmental Microbiology</u> , vol. 69, no. 4, Apr. 2003, pp. 1920-1927	
	B184	Innovate with RAFTILINE® (ORAFIT leaflet), Nov. 1996	
	B185	Innovate with RAFTILOSE® (ORAFIT leaflet), Nov. 1996	
	B186	Innovate with RAFTILOSE RAFTIMIX® (ORAFIT leaflet), Nov. 1996	
	B187	International Search Report dated Nov. 25, 2003, PCT/EP03/09384, 2 pages	
	B188	ISOLAURI et al., "Probiotics in the management of atopic eczema," <u>Clinical and Experimental Allergy</u> , vol. 30, 2000, pp. 1604-1610,	
	B189	ITO et al., "Effects of Administration of Galactooligosaccharides on the Human Faecal Microflora, Stool Weight and Abdominal Sensation," <u>Microbial Ecology in Health and Disease</u> , vol. 3, no. 6, Nov.-Dec. 1990, pp. 285-292	
	B190	ITO et al., "Influence of Lactose on Faecal Microflora in Lactose Maldigestors," <u>Microbial Ecology in Health and Disease</u> , vol. 6, 1993, pp. 73-76	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u> <i>(use as many sheets as necessary)</i>		Application Number	10/525,913
		Filing Date	09/08/2005
		First Named Inventor	HOLTUS
		Art Unit	1781
		Examiner Name	Kelly Jo Bekker
Sheet 9 of 13	Attorney Docket Number	069818-1250	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	B191	ITO et al., "Effects of Transgalactosylated Disaccharides on the Human Intestinal Microflora and Their Metabolism," <u>J. Nutr. Sci. Vitaminol.</u> , vol. 39, 1993, pp. 279-288	
	B192	ITO et al., "Influence of Galactooligosaccharides on the Human Fecal Microflora," <u>J. Nutr. Sci. Vitaminol.</u> , vol. 39, 1993, pp. 635-640	
	B193	JACOBSON et al., "Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy," <u>AIDS</u> (Hagerstown), vol. 17, no. 6, Apr. 11, 2003, pp. 917-919 (XP008052430)	
	B194	JENKINS et al., "Inulin, Oligofructose and Intestinal Function," <u>J. Nutrition</u> , vol. 129, 1999, pp. 1431S-1433S	
	B195	JIANG et al., "In Vitro Lactose Fermentation by Human Colonic Bacteria is Modified by Lactobacillus Acidophilus Supplementation," <u>American Society for Nutritional Sciences</u> , 1997, pp. 1489-1495	
	B196	KLOSE et al., Chapter 7 entitled "Gums" in <u>CRC Handbook of Food Additives</u> , 2 <sup>nd</sup> ed, edited by Furia, 1972, pp. 305-07	
	B197	KOHMOTO et al., "Effect of Isomalto-oligosaccharides on Human Fecal Flora," <u>Bifidobacteria microflora</u> , vol. 7, no. 2, 1988, pp. 61-69	
	B198	KULKARNI et al., "Immunostimulant activity of inulin isolated from Saussurea lappa roots," <u>Indian Journal of Pharmaceutical Sciences</u> , vol. 63, no. 4, Jul. 2001, pp. 292-294	
	B199	LAIDLAW et al., "Effects of supplementation with fish oil-derived n-3 fatty acids and $\gamma$ -linolenic acid on circulating plasma lipids and fatty acid profiles in women," <u>Am J Clin Nutr.</u> , vol. 77, 2003, pp. 37-42	
	B200	Listing of sales of RAFTIMIX® 10 to clients i.a. in period Sep. 13, 1996 to May 19, 1998	
	B201	Manufacture protocol with composition of RAFTIMIX® 10 1995	
	B202	MARINI et al., "Pro- and pre-biotics administration in preterm infants: colonization and influence on faecal flora," <u>Acta Paediatr. Suppl.</u> , vol. 441, 2003, pp. 80-81	
	B203	MARSHALL, "Therapeutic Applications of Whey Protein," <u>Alternative Medicine Review</u> , vol. 9, no. 2, 2004, pp. 136-156	
	B204	MARTEAU et al., "Nutritional advantages of probiotics and prebiotics," <u>British Journal of Nutrition</u> , vol. 87, Sup. 2, 2002, pp. S153-S157	
	B205	MATA et al., "Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge," <u>Vaccine</u> , vol. 19, 2001, pp. 1435-1445	
	B206	MayoClinic.com "prevention of HIV/AIDS," 4 pages, also available at <a href="http://www.mayoclinic.com/health/hiv-aids/DS00005/DSECTION=prevention">http://www.mayoclinic.com/health/hiv-aids/DS00005/DSECTION=prevention</a> , last viewed Aug. 21, 2009	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u> <i>(use as many sheets as necessary)</i>				Application Number	10/525,913
				Filing Date	09/08/2005
				First Named Inventor	HOLTUS
				Art Unit	1781
				Examiner Name	Kelly Jo Bekker
Sheet	10	of	13	Attorney Docket Number	069818-1250

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	B207	MayoClinic.com, "Ulcerative colitis," 13 pages, also available at <a href="http://www.mayoclinic.com/health/ulcerative-colitis/DS00598/METHOD=print&amp;DSECT...">http://www.mayoclinic.com/health/ulcerative-colitis/DS00598/METHOD=print&amp;DSECT...</a> , last viewed Nov. 24, 2010			
	B208	McGraw-Hill's Access Science Encyclopedia of Science & Technology Online "Acid and Base," also available at <a href="http://www.accessscience.com/content.aspx?searchStr=acid&amp;id=004400">http://www.accessscience.com/content.aspx?searchStr=acid&amp;id=004400</a> , last viewed Aug. 20, 2009			
	B209	McGraw-Hill's Access Science Encyclopedia of Science & Technology Online "oligosaccharide," also available at <a href="http://www.accessscience.com/content.aspx?searchStr=oligosaccharide&amp;id=468300">http://www.accessscience.com/content.aspx?searchStr=oligosaccharide&amp;id=468300</a> , last viewed Aug. 21, 2009			
	B210	MELEGHI et al., "New baby food milk products," <u>XXI International Dairy Congress brief communications</u> , vol. 1, book 2, Moscow, Jul. 12-16, 1982, p. 128			
	B211	Merck Manual, "Atopic and Allergic Disorders," also available at <a href="http://www.merck.com/mmpe/sec13/ch165/ch165c.html?qt=allergy&amp;alt=sh#sec13-ch165-ch165c-319">http://www.merck.com/mmpe/sec13/ch165/ch165c.html?qt=allergy&amp;alt=sh#sec13-ch165-ch165c-319</a> , last viewed Mar. 16, 2010			
	B212	MINIELLO et al., "Prebiotics in infant milk formulas: New Perspectives," <u>Acta Paediatrica Suppl.</u> , 441, 2003, pp. 68-76			
	B213	MITSUOKA, "Intestinal Flora and Human Health," <u>Asa Pacific J. Clin. Nutr.</u> , vol. 15, 1996, pp. 2-8			
	B214	MIZOTA et al., "Lactulose as a Sugar with Physiological Significance," <u>Bulletin IDF</u> , no. 212, <u>Trends in Whey Utilization</u> , 1987, chapter 11, session III, pp. 69-76			
	B215	MORI et al., "Effects of Glycyrrhizin (SNMC: Stronger Neo-Minophagen C) in hemophilia patients with HIV-1 Infection," <u>Tohoku J. Exp. Med.</u> , vol. 162, no. 2, 1990, pp. 183-193			
	B216	MORO et al., "Dosage-Related Bifidogenic Effects of Galacto- and Fructooligosaccharides in Formula-Fed Term Infants," <u>Journal of Pediatric Gastroenterology and Nutrition</u> , vol. 34, no. 3, Mar. 2002, pp. 291-295, Raven Press, NY, NY			
	B217	MORO et al., "Effects of a new mixture of prebiotics on faecal flora and stools in term infants," <u>Acta Paediatrica Suppl.</u> , vol. 91, no. 441, Sep. 2003, pp. 77-79			
	B218	MORO et al., "Reproducing the bifidogenic effect of human milk in formula-fed infants: Why and how?" <u>Acta Paediatrica Suppl.</u> , 449, vol. 94, 2005, pp. 14-17			
	B219	MURPHY, "Non-polyol low-digestible carbohydrates: food applications and functional benefits," <u>British Journal of Nutrition</u> , vol. 85, suppl. 1, 2001, pp. S47-S53			
	B220	NAKANO et al., "Anti-Human Immunodeficiency Virus Activity of Oligosaccharides from Rooibos Tea ( <i>Aspalathus Linearis</i> ) Extracts in Vitro," <u>Leukemia</u> , vol. 11, no. suppl. 3, Macmillan Press Ltd., US, 1997, pp. 128-130			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u> <i>(use as many sheets as necessary)</i>				Application Number	10/525,913
				Filing Date	09/08/2005
				First Named Inventor	HOLTUS
				Art Unit	1781
				Examiner Name	Kelly Jo Bekker
Sheet	11	of	13	Attorney Docket Number	069818-1250

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	B221	ORAFIT, "inulin," also available at <a href="http://www.orafit.com/Our-Products/Inulin">http://www.orafit.com/Our-Products/Inulin</a> , last viewed Mar. 15, 2010		
	B222	PARCELL, "Sulfur in Human Nutrition and Applications in Medicine," <u>Alternative Medicine Review</u> , vol. 7, no. 1, Feb. 2002, pp. 22-24, Thorne Research Inc., Sandpoint, US		
	B223	Patent Abstracts of Japan, vol. 013, no. 408 (C-634), Sep. 8, 1989 (JP 01 149730 A, Jun. 12, 1989)		
	B224	Patent Abstracts of Japan, vol. 017, no. 119 (C-1034), Mar 12, 1993 (JP 04 300888 A, Oct. 23, 1992)		
	B225	RAFTILINE® HP Product Sheet Release: May 1995		
	B226	RAFTILINE® ST Product Sheet Release: May 1995		
	B227	RAFTILOSE® P95 Product Sheet Release: May 1995		
	B228	RAFTIMIX® 10 Product Sheet Release: May 1995		
	B229	REDDY et al., "Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition," <u>Carcinogenesis</u> , vol. 18, no. 7, 1997, pp. 1371-1374		
	B230	REICH et al, "Tonicity, Osmoticity, Osmolality, and Osmolarity," in Remington: <u>The Science and Practice of Pharmacy</u> , 20 <sup>th</sup> ed, edited by Gennaro, 2000, pp. 246-56		
	B231	RIGO et al., "Growth, Weight Gain Composition and Mineral Accretion in Term Infants Fed a New Experimental Formula Containing Hydrolysed Protein, Beta-Palmitate and Prebiotics," <u>Pediatrics</u> , <u>Alpe</u> , Madrid, Spain, vol. 21, no. 10, 2001, pp 387-396		
	B232	ROBERFROID, "Dietary Fiber, Inulin, and Oligofructose: a review comparing their physiological effects," <u>Critical Reviews in Food Science and Nutrition</u> , vol. 33, no. 2, 1993, pp. 103-148		
	B233	ROBERFROID et al., "Health Benefits of Non-Digestible Oligosaccharides," <u>NCBI Pub Med</u> , 1997		
	B234	ROBERFROID, et al, "The Bifidogenic Nature of Chicory Inulin and its Hydrolysis Products," <u>The Journal of Nutrition</u> , vol. 128, 1998, pp. 11-19		
	B235	ROBERFROID, "Prebiotics: preferential substrates for specific germs?," <u>Am J. Clin. Nutr.</u> , vol. 73 (suppl), 2001, pp. 406S-409S		
	B236	ROTIMI et al, "The Development of the Bacterial Flora in Normal Neonates," <u>J. Med. Microbiol.</u> , vol. 14, 1981, pp. 51-62		
	B237	RUBALTELLI et al., "Intestinal Flora in Breast- and Bottle-fed Infants," <u>J. Perinat. Med.</u> , vol. 26, 1998, pp. 186-191		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u>  (use as many sheets as necessary)				Application Number	10/525,913
				Filing Date	09/08/2005
				First Named Inventor	HOLTUS
				Art Unit	1781
				Examiner Name	Kelly Jo Bekker
Sheet	12	of	13	Attorney Docket Number	069818-1250

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	B238	SALMINEN et al., "Functional food science and gastrointestinal physiology and function," <u>British Journal of Nutrition</u> , vol. 80, suppl. 1, 1998, pp. S147-S171		
	B239	SANSONI, "Lymphocyte Subsets and Natural Killer Cell Activity in Healthy Old People and Centenarians," <u>Blood</u> , vol. 82, no. 9, Nov. 1, 1993, pp. 2767-2773		
	B240	SCHMELZLE et al, "Randomized Double-Blind Study of the Nutritional Efficacy and Bifidogenicity of a New Infant Formula Containing Partially Hydrolyzed Protein, a High $\beta$ -Palmitic Acid Level, and Nondigestible Oligosaccharides," <u>J. Pediatr. Gastroenterol. Nutr.</u> , vol. 36, issue 3, Mar. 2003, pp. 343-351		
	B241	SIMOPOULOS et al., "Workshop on the Essentiality of and Recommended Dietary Intakes for Omega-6 and Omega-3 Fatty Acids," <u>Journal of the American College of Nutrition</u> , vol. 18, no. 5, 1999, pp. 487-489		
	B242	TANAKA et al., "Effects of Administration of TOS and Bifidobacterium breve 4006 on the Human Fecal Flora," <u>Bifidobacteria Microflora</u> , vol. 2, no. 1, 1983, pp. 17-24		
	B243	TERADA et al., "Effect of Lactosucrose on Fecal Flora and Fecal Putrefactive Products of Cats," <u>NCBI PubMed</u> , 1993		
	B244	Think RAFTILINE®, RAFTILOSE®, Inuline and Oligofructose, (Orafti brochure), Apr. 23, 2008		
	B245	USAMI et al, "Effect of eicosapentaenoic acid (EPA) on tight junction permeability in intestinal monolayer cells," <u>Clinical Nutrition</u> , vol. 20, no. 4, 2001, pp. 351-359		
	B246	VAN LAERE et al., "Mogelijkheden en toepassingen van prebiotica: Possibilities and applications of prebiotics," <u>Voedingsmiddelen Technologie</u> , Noordervliet B.V. Zeist, NL, vol. 34, no. 23, Oct. 26, 2001, pp 51-54 (XP008029566; ISSN: 0042-7934)		
	B247	VAN LOO et al., "On the Presence of Inulin and Oligofructose as Natural Ingredients in the Western Diet," <u>Critical Reviews in Food Science and Nutrition</u> , vol. 35, no. 6, 1995, pp. 525-552		
	B248	WATANABE et al., "Therapeutic Effects of Glycyrrhizin in Mice Infected with LP-BM5 Murine Retrovirus and Mechanisms Involved in the Prevention of Disease Progression," <u>Biotherapy</u> , vol. 9, no. 4, 1996, pp. 209-220, Kluwer Academic Publishers, Dordrecht, NL		
	B249	WATZL et al., "Inulin, oligofructose and immunomodulation," <u>British Journal of Nutrition</u> , vol. 93, no. 1, 2005, pp. S49-S55 [XP002474088]		
	B250	WordNet Search 3.0 "prevent"; also available at <a href="http://wordnetweb.princeton.edu/perl/webwn">http://wordnetweb.princeton.edu/perl/webwn</a> ; last viewed Mar.16, 2010		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: <u>December 28, 2010</u> <i>(use as many sheets as necessary)</i>		Application Number	10/525,913
		Filing Date	09/08/2005
		First Named Inventor	HOLTUS
		Art Unit	1781
		Examiner Name	Kelly Jo Bekker
Sheet 13 of 13	Attorney Docket Number	069818-1250	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
.	B251	YAZAWA et al., "Search for Sugar Sources for Selective Increase of Bifidobacteria," <u>Bifidobacteria microflora</u> , vol. 1, no. 1, 1982, pp. 39-44	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.